Enterprise Value
0.00
Cash
52.2M
Avg Qtr Burn
N/A
Short % of Float
7.33%
Insider Ownership
15.80%
Institutional Own.
55.80%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AXA1125 Details COVID-19 | Phase 2/3 Initiation | |
AXA1125 Details Non-alcoholic steatohepatitis , Fatty liver disease, Liver disease | Failed Discontinued | |
AXA1665 Details Liver disease, Overt hepatic encephalopathy | Failed Discontinued |